Antoine Italiano, MD
Larotrectinib (Vitrakvi) demonstrated a clinically meaningful improvement in progression-free survival (PFS) compared with time to progression (TTP) on prior treatment in patients with TRK
fusion–positive cancers using a measure known as the growth modulation index (GMI), according to results of an analysis presented at the 2019 ESMO Congress.
Caveats to the data, according to the authors, are that: 1) GMI underestimates the clinical benefit in patients on treatment who have not progressed at the time of analysis, 2) patients with the poorest prognosis may have been excluded as patients had to have received at least 1 prior line of therapy for inclusion, and 3) TTP data on the most recent prior treatment were provided by physicians.
Italinao A, Nanda S, Keating K, et al. Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients. Presented at 2019 ESMO Congress; September 27-October 2, 2019; Barcelona, Spain. Abstract 485P.Nat Med. doi:10.1038/nm.4118.
<<< View more from the 2019 ESMO Congress
... to read the full story